Uliledlimab

Recently announced agreement to divest assets and business operations in China marks an important milestone for the Company; the transaction is expected to close by the end of March 2024 Uliledlimab (CD73 antibody) on track to file an IND in combination with chemotherapy and checkpoint inhibitors for patients with newly diagnosed NSCLC in 1H 2024 First patient dosed in an ongoing, triplet combination, dose escalation study of givastomig (CLDN18.2x4-1BB bispecific antibody) in 1Q 2024 RMB2.3 billion (US$321.8 million) in cash and cash equivalents, and short-term investments as of December 31, 2023 ROCKVILLE, Md., March 14, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced financial results for the full year ended December 31, 2023, and highlighted recent business updates. "2023 was a transitional year for I-Mab and we were pleased to report encouraging clinical results in our two lead global assets in oncology, uliledlimab and givastomig. As we prepare for the closing of the strategic divestiture, we look forward to providing investors with a road map to value creation and believe that our differentiated clinical assets, uliledlimab, givastomig, and ragistomig will achieve critical milestones and trial initiations this year," said Raj Kannan, Director and Chief Executive Officer of I-Mab. Pipeline Overview and Upcoming Milestones: Uliledlimab: Phase 2, with a focus on non-small cell lung cancer (NSCLC) Uliledlimab is designed to target CD73 and promote stronger activation of the patient's immune system against cancer cells. Uliledlimab is potentially differentiated from other products in development due to its non-competitive binding with adenosine monophosphate and the potential for complete inhibition of CD73's immune dampening function. Encouraging results from a Phase 2 study of uliledlimab in combination with toripalimab, presented at the American Society for Clinical Oncology (ASCO 2023) in patients with advanced NSCLC, provided compelling support for further development of uliledlimab. In particular, the subset of patients with both high CD73 expression and PD-L1 TPS>1% showed an impressive 63% overall response rate. Additionally, enrollment of patients with treatment resistant ovarian cancer has been completed, and ongoing efforts will be streamlined to focus on expediting NSCLC development. Upon the receipt of the investigational new drug (IND) approval, the Company plans to initiate the triplet study for uliledlimab in combination with chemotherapy and checkpoint inhibitors in newly diagnosed patients with advanced NSCLC in the second half of 2024. Givastomig (Claudin 18.2 x 4-1BB bispecific antibody): Phase 1b, with a focus on gastric cancer and esophageal adenocarcinoma Givastomig was designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Phase 1 monotherapy data presented at the European Society of Medical Oncology (ESMO 2023) showed encouraging objective responses in patients with gastric cancer and esophageal adenocarcinoma whose tumors progressed or recurred after prior standard treatments, including those with low levels of Claudin 18.2 expression. This program is being jointly developed with ABL Bio. I-Mab owns 50% of the global rights of givastomig. The enrollment of patients from the U.S. and China with newly diagnosed (frontline treatment) gastric and esophageal cancer in combination with chemotherapy and a checkpoint inhibitor began in the first quarter of 2024. Ragistomig (PD-L1 x 4-1BB bispecific antibody): Phase 1 dose escalation, with a focus on solid tumors Ragistomig was designed as a bispecific antibody to address PD-L1 resistant tumors, differentiated by the conditional activation of 4-1BB's pro-immune stimulation when it binds to its PD-L1 target. Early observations reported by our development partner, ABL Bio, showed promising objective responses in patients with various solid tumors whose tumors progressed or recurred after prior standard treatments, including in patients with relapsed or refractory cancer after prior PD-L1 inhibitors. These early signs of efficacy are encouraging, and enrollment in the Phase 1 study continues. This program is being jointly developed with ABL Bio. I-Mab owns 50% of the global rights of ragistomig (TJ-L14B/ABL503). Top-line Phase 1 dose escalation and dose expansion results are expected to be presented at a major medical conference in the first half of 2024. Impact of Strategic Transaction on Pipeline The agreement to divest assets and business operations in China, previously announced in a press release on February 7, 2024, is expected to be completed by the end of March 2024. Upon the closing of the transaction, the Greater China rights for assets including eftansomatropin alfa, felzartamab, uliledlimab, and givastomig will be transferred to I-Mab Biopharma (Hangzhou) Co., Ltd., an unconsolidated affiliate (the " Hangzhou Company"). I-Mab will no longer bear future development costs of these divested assets in China and may receive an aggregate consideration of the RMB equivalent of up to US$80 million, contingent on the Hangzhou Company group's achievement of certain future regulatory and sales-based milestone events relating to these divested assets in China. The transaction, if closed, will also extinguish existing repurchase obligations owed by a wholly-owned subsidiary of the Company in the amount of approximately US$183 million. As a result of the closing of the transaction, the Company will cease consolidation of the divested entities, assets, and businesses as well as their corresponding financial results. The Company's financial condition and results of operations will be materially affected and the Company's historical results will not be indicative of future financial condition or results of operations. Full-Year 2023 Financial Results Cash Position As of December 31, 2023, the Company had cash, cash equivalents, and short-term investments of RMB2.3 billion (US$321.8 million), compared with RMB3.5 billion as of December 31, 2022. Share Buyback In August 2023, the Board of Directors of the Company authorized a new share repurchase program under which the Company may repurchase up to US$40 million of American Depository Shares ("ADSs"), each ten ADSs representing 23 ordinary shares of the Company, or ordinary shares in aggregate over a 12-month period. During the period ended December 31, 2023, the Company repurchased US$8.6 million of its ADSs, equating to 4,633,386 ADSs or 10,656,794 ordinary shares. As of December 31, 2023, the Company had issued and outstanding ordinary shares of 185,613,662, representing the equivalent of 80,701,592 ADSs assuming the conversion of all ordinary shares into ADSs. Net Revenues Total net revenues for the full year of 2023 were RMB27.6 million (US$3.9 million), compared with RMB-221.6 million (US$-32.1 million) for the full year of 2022. Total net revenues in 2023 consisted of revenues recognized in connection with the strategic collaboration with AbbVie Inc. (AbbVie) and revenues generated from the supply of investigational products to AbbVie and Human Immunology Biosciences, Inc. The negative figure for net revenue in 2022 was primarily due to a one-time, non-cash accounting treatment of US$-48.0 million (equivalent to RMB-314.2 million) recorded in the second half of 2022 following the amendment to the original license and collaboration agreement with AbbVie in August 2022. This amendment led to a reduced probability of achieving a key milestone that was included in the consideration of revenue recognition in prior years. Research & Development Expenses Research and development expenses for the full year of 2023 were RMB810.6 million (US$114.2 million), compared with RMB904.9 million (US$131.2 million) for the full year of 2022. The decrease was primarily due to reduced payroll expenses related to headcount optimization as a result of asset prioritization and reduced share-based compensation expenses. Share-based compensation expense was RMB66.8 million (US$9.4 million) for the full year of 2023, compared with RMB117.9 million (US$17.1 million) for the full year of 2022. Administrative Expenses Administrative expenses for the full year of 2023 were RMB453.0 million (US$63.8 million), compared with RMB815.8 million (US$118.3 million) for the full year of 2022. The decrease was primarily due to reduced payroll expenses related to decreased headcount as a result of resource optimization and reduced share-based compensation expenses for management personnel, reduced expenses for professional services, and reduced legal expenses in relation to the disputes with Tracon Pharmaceuticals, Inc. of RMB95.5 million (US$13.5 million). Share-based compensation expense was RMB126.2 million (US$17.8 million) for the full year of 2023, compared with RMB239.3 million (US$34.7 million) for the full year of 2022. Other Expenses, Net Net other expenses for the full year of 2023 were RMB38.1 million (US$5.4 million), compared with RMB126.6 million (US$18.4 million) for the full year of 2022. The change was primarily driven by unrealized exchange rate losses due to the significant fluctuation in the exchange rate of the Renminbi against the U.S. dollar in 2022. Equity in Loss of Affiliates Equity in loss of affiliates for the full year of 2023 was RMB80.0 million (US$11.3 million), compared with RMB437.5 million (US$63.4 million) for the full year of 2022. The loss was mainly recognized in relation to the operating loss of the Company's investee, I-Mab Biopharma (Hangzhou) Co., Ltd. Impairment of Goodwill For the full year of 2023, the Company recognized an impairment of goodwill of RMB162.6 million (US$22.9 million). The goodwill impairment resulted from the Company's annual impairment analysis, and reflects the continued disconnect between I-Mab's anticipated future performance and present uncertainty reflected in its market valuation. Net Loss Net loss for the full year of 2023 was RMB1,465.7 million (US$206.4 million), compared with RMB2,507.3 million (US$363.5 million) for the year 2022. Net loss per share attributable to ordinary shareholders for the full year of 2023 was RMB7.19 (US$1.01), compared with RMB13.21 (US$1.92) for the full year of 2022. Net loss per ADS attributable to ordinary shareholders for the full year of 2023 was RMB16.54 (US$2.33), compared with RMB30.38 (US$4.41) for the full year of 2022. Non-GAAP Net Loss Non-GAAP adjusted net loss, which excludes share-based compensation expenses and impairment of goodwill, for the full year of 2023 was RMB1,105.3 million (US$155.7 million), compared with RMB2,136.3 million (US$309.7 million) for the full year of 2022. Non-GAAP adjusted net loss per share attributable to ordinary shareholders for the full year of 2023 was RMB5.42 (US$0.76), compared with RMB11.26 (US$1.63) for the full year of 2022. Non-GAAP adjusted net loss per ADS attributable to ordinary shareholders for the full year of 2023 was RMB12.47 (US$1.76), compared with RMB25.90 (US$3.75) for the full year of 2022. Use of Non-GAAP Financial Measures To supplement its consolidated financial statements, which are presented in accordance with U.S. GAAP, the Company uses adjusted net income (loss) as a non-GAAP financial measure. Adjusted net income (loss) represents net income (loss) before share-based compensation and impairment of goodwill. The Company's management believes that adjusted net income (loss) facilitates understanding of operating results and provides management with a better capability to plan and forecast future periods. For more information on the non-GAAP financial measures, please see the table captioned "Reconciliation of GAAP and Non-GAAP Results" set forth at the end of this press release. Non-GAAP information is not prepared in accordance with GAAP and may be different from non-GAAP methods of accounting and reporting used by other companies. The presentation of this additional information should not be considered a substitute for GAAP results. A limitation of using adjusted net income (loss) is that adjusted net income (loss) excludes share-based compensation expense and impairment of goodwill that has been and may continue to be incurred in the future. Exchange Rate Information This announcement contains translations of certain Renminbi amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from Renminbi to U.S. dollars of the financial results for the year of 2023 are made at a rate of RMB7.0999 to US$1.00, the rate in effect as of December 29, 2023, published by the Federal Reserve Board. All translations from Renminbi to U.S. dollars of the financial results for the year of 2022 are made at a rate of RMB6.8972 to US$1.00, the rate in effect as of December 30, 2022 published by the Federal Reserve Board. Notes: (1) Includes share-based compensation expense of RMB117,876 thousand (US$17,090 thousand) and RMB66,758 thousand (US$9,403 thousand) for the years ended December 31, 2022 and 2023, respectively. (2) Includes share-based compensation expense of RMB239,272 thousand (US$34,691 thousand) and RMB126,244 thousand (US$17,781 thousand) for the years ended December 31, 2022 and 2023, respectively. (3) Includes share-based compensation expense of RMB13,852 (US$2,008 thousand) and RMB4,815 thousand (US$678 thousand) for the years ended December 31, 2022 and 2023, respectively. (4) Each ten ADSs represents twenty-three ordinary shares. About I-Mab I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in the U.S. in Rockville, Maryland, and in San Diego, California. For more information, please visit and follow us on LinkedIn, X, and WeChat. I-Mab Forward Looking Statements This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will", "expects", "believes", "designed to", "anticipates", "future", "intends", "plans", "potential", "estimates", "confident", and similar terms or the negative thereof. I-Mab may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about I-Mab's beliefs and expectations, are forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding: the timing of the completion of the expected divestiture of the Company's assets and business operations in China and its anticipated impact on the Company (including the transfer of Greater China rights for assets, including eftansomatropin alfa, felzartamab, uliledlimab, and givastomig to the Hangzhou Company, the expected consideration to be received by I-Mab and the expected extinguishment of an existing repurchase obligation of US$183 million); the Company's expectations regarding providing a road map to value creation and its belief that its clinical oncology programs will achieve critical milestones and trial initiations this year; the Company's pipeline overview and upcoming anticipated milestones, including with respect to uliledlimab, givastomig, and ragistomig, and the intended impact and the Company's plans with respect thereto. Forward-looking statements involve inherent risks and uncertainties that may cause actual results to differ materially from those contained in these forward-looking statements, including but not limited to the following: I-Mab's ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may or may not support further development or New Drug Application/Biologics License Application (NDA/BLA) approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of I-Mab's drug candidates; I-Mab's ability to achieve commercial success for its drug candidates, if approved; I-Mab's ability to obtain and maintain protection of intellectual property for its technology and drugs; I-Mab's reliance on third parties to conduct drug development, manufacturing and other services; and I-Mab's limited operating history and I-Mab's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, as well as those risks more fully discussed in the "Risk Factors" section in I-Mab's most recent annual report on Form 20-F, as well as discussions of potential risks, uncertainties, and other important factors in I-Mab's subsequent filings with the SEC. All forward-looking statements are based on information currently available to I-Mab. I-Mab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. For more information, please contact: I-Mab Contacts SOURCE I-Mab

点击蓝字关注我们本周，仍有不少值得注意的热点。首先是审评审批方面，先看国内，勃林格殷格翰IL-36R单抗皮下注射剂型在中国获批上市。再看国外，泽布替尼成为全球首个也是唯一一个获批用于FL的BTK抑制剂以及FDA批准首款地舒单抗生物类似药上市。其次是研发方面，多个重要临床已经启动，例如天境生物CD73单抗启动Ⅲ期临床，一线治疗非小细胞肺癌。最后是交易及投融资方面，罗欣药业与未知君推动肠道菌群移植达成商业化合作。本期盘点包括审评审批、研发、交易及投融资三大板块，统计时间为3.4-3.8，包含24条信息。 审评审批NMPA上市批准1、3月6日，NMPA官网显示，勃林格殷格翰（BoehringerIngelheim）的佩索利单抗注射液（皮下注射）获批上市，用于减少12岁及以上青少年（体重≥40kg）和成人的泛发性脓疱型银屑病（GPP）。佩索利单抗是一款选择性靶向白细胞介素-36受体（IL-36R）的抗体。此前该产品静脉注射制剂已在中国获批用于治疗成人GPP发作。申请2、3月4日，CDE官网显示，葆元医药的己二酸他雷替尼胶囊新适应症申报上市，推测用于未经ROS1-TKI治疗的ROS1阳性局部晚期或转移性NSCLC成人患者。他雷替尼是一种口服、强效、脑渗透、选择性、新一代潜在最佳的ROS1抑制剂，此前拟被纳入优先审评。3、3月5日，CDE官网显示，复宏汉霖的阿达木单抗注射液生物类似药（商品名：汉达远）新适应症申报上市，用于多关节型幼年特发性关节炎、儿童斑块状银屑病等自身免疫疾病的治疗。阿达木单抗是一款全人源抗肿瘤坏死因子α（TNF-α）单克隆抗体。4、3月8日，CDE官网显示，Ascendis Pharma、维昇药业（VISENPharmaceuticals）的注射用隆培促生长素申报上市，用于治疗儿童生长激素缺乏症。隆培促生长素是一款长效生长激素（每周注射一次），在此前治疗中国生长激素缺乏症儿童的Ⅲ期关键临床试验中，该产品治疗52周后，年化生长速率为10.66厘米/年。临床批准       5、3月4日，CDE官网显示，复星医药子公司精缮生物的1类新药GCK-01细胞注射液获批临床，拟用于治疗复发或难治性滤泡性淋巴瘤（FL）。GCK-01是精缮生物自主研发的一款靶向CD20的NK细胞疗法。CD20抗原在许多B细胞恶性肿瘤上表达。6、3月5日，CDE官网显示，靖因药业（SiriusTherapeutics）的SRSD107注射液获批临床，拟用于治疗预防或治疗动静脉血栓。SRSD107是一款双链小干扰核酸（siRNA）药物，属于新一代抗凝药物，正在澳大利亚开展Ⅰ期临床试验。7、3月5日，CDE官网显示，星盛新辉的XS-02胶囊获批临床，拟用于治疗晚期实体瘤。XS-02是星盛新辉研发的一款小分子CHK1抑制剂，能特异性抑制CHK1生理功能，且具有良好的口服生物利用度。8、3月6日，CDE官网显示，康弘药业全资子公司康弘生物的KH801注射液获批临床，拟用于治疗晚期实体瘤。KH801注射液是康弘生物自主研发的抗CD24人源化单克隆抗体，能与肿瘤细胞上的CD24特异性结合，通过阻断CD24/Siglec-10“别吃我”信号，提高肿瘤相关巨噬细胞（TAM）对肿瘤细胞的吞噬作用。9、3月7日,CDE官网显示，强生旗下强生创新制药的1类新药JNJ-80948543注射液获批临床，拟开发治疗淋巴细胞恶性肿瘤。NJ-80948543是一款新型CD79bxCD20xCD3三特异性T细胞重定向抗体，可与T细胞上的CD3抗原以及B细胞上的CD79b和CD20结合，从而导致恶性B细胞溶解。10、3月7日，CDE官网显示，复融生物的1类新药FL115注射液获批临床，拟开发治疗不可切除局部晚期或转移性实体瘤。FL115注射液是复融生物自主开发的一款白介素15（IL-15）超级免疫激动剂，此前已在美国进行Ⅰ期临床试验，目前已完成首例受试者给药。11、3月7日，CDE官网显示，远大医药的GPN00884获批临床，拟用于延缓儿童近视进展。GPN00884是一款延缓近视进展的创新药。与低浓度阿托品滴眼液相比，GPN00884滴眼液无瞳孔散大效应，不会出现畏光、调节下降等不良反应，给药时段不受限制，可提高患者的依从性。优先审评12、3月6日，CDE官网显示，强生旗下强生创新制药的古塞奇尤单抗注射液拟纳入优先审评，用于治疗中重度活动性克罗恩病成人患者。古塞奇尤单抗（guselkumab）是一款白介素（IL）-23抑制剂，此前已经在中国获批治疗银屑病。突破性疗法13、3月4日，CDE官网显示，映恩生物的注射用DB-1303拟纳入突破性治疗品种，拟用于治疗既往免疫检查点抑制剂（ICI）治疗期间或治疗后进展的晚期、复发性或转移性HER2表达子宫内膜癌。DB-1303为第三代靶向人表皮生长因子受体2（HER2）的抗体偶联药物（ADC），此前已经被FDA授予针对子宫内膜癌的突破性疗法认定和快速通道资格。FDA上市批准14、3月5日，FDA官网显示，山德士的地舒单抗生物类似药（商品名：Wyost/Jubbonti）获批上市。Wyost（120mg/1.7mL）可与Xgeva互换，用于治疗多发性骨髓瘤和实体瘤骨转移引起的骨骼相关事件、骨巨细胞瘤和癌症所致的高钙血症；Jubbonti（60mg/1mL）可与Prolia互换，适用于骨质疏松症。该产品也是FDA批准的第一款地舒单抗生物类似药。15、3月7日，FDA官网显示，远大医药的激素纳米混悬滴眼液GPN00833获批上市，用于眼科术后抗炎镇痛。GPN00833是一款激素纳米混悬滴眼液，其主要活性成分丙酸氯倍他索是一种强效的糖皮质激素，具有高效的局部抗炎活性和较强的毛细血管收缩作用。远大医药拥有该产品在中国大陆、中国香港和中国澳门地区的独家开发和商业化权利。16、3月7日，FDA官网显示，百济神州的泽布替尼第5项适应症获批，联合CD20单抗奥妥珠单抗治疗既往至少经过二线治疗后复发或难治性（R/R）滤泡性淋巴瘤（FL）成人患者。这标志着泽布替尼成为了首个也是唯一一个获批5项肿瘤适应症的BTK抑制剂，也是首个也是唯一一个获批用于FL的BTK抑制剂。申请17、3月6日，FDA官网显示，Epitomee公司通过510(k)途径递交减肥胶囊的上市申请。该减肥胶囊已经在欧盟获得批准，并带有CE标志。Epitomee减肥胶囊是一种模仿固体食物的变形胶囊，可激活大脑和胃中调节食物摄入的关键途径，具有良好的安全性和耐受性，用于超重和轻度肥胖人群。研发临床状态18、3月5日，中国药物临床试验登记与信息公示平台显示，华博生物和华奥泰生物已经启动了一项评价HB0017注射液治疗中重度斑块状银屑病的疗效和安全性的多中心、随机、双盲、安慰剂对照的Ⅲ期临床研究。HB0017是华奥泰自主研发的以白介素-17A（IL-17A）为靶点的单克隆抗体，拟开发用于治疗中重度斑块状银屑病和强直性脊柱炎。19、3月7日，中国药物临床试验登记与信息公示平台显示，天境生物已经启动了一项TJ004309注射液针对晚期非小细胞肺癌一线治疗的Ⅱ/Ⅲ期临床研究。TJ004309是天境生物研发的高度差异化的CD73人源化单克隆抗体尤莱利单抗（uliledlimab，也称为TJD5或TJ004309）。20、3月8日，中国药物临床试验登记与信息公示平台显示，安进已经启动一项国际多中心（含中国）Ⅲ期临床研究，旨在评估KRAS抑制剂sotorasib联合铂类双药化疗。用于PD-L1阴性且KRASp.G12C阳性的Ⅳ期或晚期ⅢB/C期非鳞状非小细胞肺癌患者一线治疗的有效性和安全性。临床数据21、3月8日，箕星药业公布了酒石酸伐尼克兰鼻喷雾剂治疗中国干眼人群的Ⅲ期临床研究，结果显示，伐尼克兰鼻喷雾剂在每日两次的应用下，对干眼展现出了临床意义上的有效性，且维持着良好的安全性和耐受性。伐尼克兰鼻喷雾剂是一种高选择性的胆碱能受体激动剂，2023年，CDE受理了伐尼克兰鼻喷雾剂的新药上市申请。22、3月8日，和铂医药公布了巴托利单抗（batoclimab）的一项Ⅲ期临床研究结果。该研究数据显示出巴托利单抗在治疗重症肌无力方面的有效性和安全性。巴托利单抗是和铂医药从HanAllBiopharma引进的一款抗FcRn单抗，和铂医药拥有其在大中华区进行开发、制造和商业化的权利。交易及投融资23、3月4日，拜耳宣布，已从Eidos和BridgeBio公司引进acoramidis在欧洲的独家商业化权益。根据协议条款，BridgeBio及其附属公司将获得高达3.1亿美元的前期和近期里程碑付款，并有资格获得额外的未披露销售里程碑付款和分级版税。Acoramidis是一款在研的口服高效转甲状腺素蛋白（TTR）小分子稳定剂。24、3月7日，罗欣药业宣布，和未知君建立长期战略合作伙伴关系，未知君将肠道菌群移植（FecalMicrobiotaTransplantation，简称FMT）治疗解决方案授权罗欣药业，在双方约定区域和渠道范围内开展独家商业化合作。双方在优势互补、互惠互利的基础上，共同加速FMT治疗的商业化进程。【智药研习社近期直播预告】来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com▼更多制药资讯，请关注CPHI制药在线▼点击阅读原文，进入智药研习社~